Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Open-label, Randomized, Standard of Care Controlled, Dose-ranging Safety and Efficacy Study of Dovramilast in People With Moderate to Severe Acute or Recurrent Leprosy Type 2 Reaction

NCT07172659 is registered in ClinicalTrials.gov with Medicines Development for Global Health as lead sponsor.

NCT NCT07172659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07172659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Open-label, Randomized, Standard of Care Controlled, Dose-ranging Safety and Efficacy Study of Dovramilast in People With Moderate to Severe Acute or Recurrent Leprosy Type 2 Reaction
Lead sponsor
Medicines Development for Global Health
Phase
Phase 2
Overall status
Recruiting
Start date
September 15, 2026
Completion date
December 31, 2027
Enrollment
45 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

erythema nodosum leprosum